A new immunotherapy using natural killer cells showed promise in a small proof-of-concept Phase 1 trial of relapsed or refractory…
Articles by Magdalena Kegel
A combination treatment of four drugs including the chemotherapy agent Alkeran (melphalan) gives excellent short-term outcomes in multiple myeloma patients…
A new type of dendritic cell-based immunotherapy triggered an immune response in the majority of patients in a small Phase…
Researchers have discovered a mechanism underlying the development of treatment resistance to proteasome inhibitors in multiple myeloma. Surprisingly, the mechanism…
Patients in a precancerous stage of multiple myeloma would be wise to avoid gaining extra weight, according to new research that…
A combination of nonspecific symptoms, including back pain and weight loss, should alert physicians to the possibility of multiple myeloma. Still,…
Combining three well-known oral drugs shows potential for heavily pretreated multiple myeloma patients who have grown resistant to therapy with one…
The Multiple Myeloma Research Foundation (MMRF) is going to add its entire worth of genomic data to the Genomic…
Minimal residual disease, a measurement that shows a low level of disease detected, should be used as an endpoint in…
Adding Darzalex (daratumumab) to the treatment of multiple myeloma with Velcade (bortezomib) and dexamethasone significantly improved progression-free survival in a…